Development · 22 Sep 2026
3 publishers have reported this development. Each act of reporting is below, cited.
Akums Drugs and Pharmaceutical announced that it has secured approval to market a combikit of clarithromycin, vonoprazan, and amoxicillin for the treatment of Helicobacter pylori infection in adults.
Akums Drugs & Pharmaceuticals has announced the development of a DCGI-approved Clarithromycin + Vonoprazan + Amoxicillin Combikit for the treatment of Helicobacter pylori infection in adults.
Akums Drugs & Pharmaceuticals has developed a DCGI-approved triple therapy combikit for the treatment of Helicobacter pylori infection in adults.
This page is the corroborated record of one development: what each credible source reported, linked and dated. We compile and cite; we do not opine.
New here? The reader's guide explains every page, plate by plate.
fregime is informational research software. Content on this page is factual reporting compiled from cited public sources; nothing here is advice, and nothing here expresses an opinion on any security. fregime is not registered with SEBI as an investment adviser or research analyst. Before making investment decisions, consult a SEBI-registered adviser. Price figures are delayed end-of-day values cited to the exchange's published file, never live quotes.